Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiME: Rucaparib + Ramucirumab +/- Nivolumab in Advanced Gastric/Esophageal Cancer
NCT03995017Phase 2Unknown
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rucaparib in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by University of Kansas Medical Center. Status: unknown.
02
Drugs
rucaparib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03995017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995017.